Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors

Hiroyuki Mizoguchi, Kiyofumi Yamada, Makoto Mizuno, Tomoko Mizuno, Atsumi Nitta, Yukihiro Noda, Toshitaka Nabeshima

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Little is known about molecular mechanisms for long-lasting neuroadaptation related to the rewarding effects of methamphetamine (MAP). In the present study, we examined the intracellular signaling that is associated with the expression of conditioned place preference (CPP) induced by MAP in rats. Rats were given MAP or saline (control group) for conditioning to the CPP test. MAP-treated and control animals were killed immediately after the CPP test [CPP+]. Some of the MAP-treated rats were killed without the CPP test [CPP-]. Hyperphosphorylation of mitogen-activated protein kinase (MAPK) ERK1/2, but not p38 and c-Jun N-terminal kinase/stress-activated protein kinase, was found in the nucleus accumbens (NAc) and striatum but not in other brain areas of MAP-treated CPP+ animals. No such phosphorylation was seen in control and MAP-treated CPP- animals. Moreover, the transcription factor ets-like gene-1 (Elk-1), but not cAMP response element-binding protein, also showed a similar hyperphosphorylation in the same regions of MAP-treated CPP+. Tyrosine kinase receptors, including tyrosine kinase B, were not activated in any brain regions examined in all groups. Both the dopamine D1 receptor antagonist R-(+)-7-chloro-8-hydroxy-3- methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH23390) and the D2 receptor antagonist raclopride inhibited the expression of CPP as well as the activation of ERK1/2 in MAP-treated CPP+ animals, when they were injected before the CPP test. The microinjection of 2′-amino-3′- methoxyflavone (PD98059), a selective MAPK kinase inhibitor, into the NAc before the test, abolished the MAP-induced ERK1/2 activation and decreased the expression of MAP-induced CPP. These results suggest the importance of the ERK1/2 signaling pathway through activation of dopamine D1 and D2 receptors in the expression of CPP induced by MAP.

Original languageEnglish
Pages (from-to)1293-1301
Number of pages9
JournalMolecular Pharmacology
Volume65
Issue number5
DOIs
Publication statusPublished - 01-05-2004
Externally publishedYes

Fingerprint

Mitogen-Activated Protein Kinase 3
Methamphetamine
Mitogen-Activated Protein Kinase 1
Dopamine Receptors
Reward
Genes
Dopamine D1 Receptors
Nucleus Accumbens
Proto-Oncogene Proteins c-ets
Raclopride
Cyclic AMP Response Element-Binding Protein
Dopamine Antagonists
Dopamine D2 Receptors
MAP Kinase Signaling System
JNK Mitogen-Activated Protein Kinases
Mitogen-Activated Protein Kinase Kinases
Brain
Microinjections
Receptor Protein-Tyrosine Kinases
Heat-Shock Proteins

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

Mizoguchi, Hiroyuki ; Yamada, Kiyofumi ; Mizuno, Makoto ; Mizuno, Tomoko ; Nitta, Atsumi ; Noda, Yukihiro ; Nabeshima, Toshitaka. / Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors. In: Molecular Pharmacology. 2004 ; Vol. 65, No. 5. pp. 1293-1301.
@article{fb3d4622848e4e0b917ed46f5bbdeaf8,
title = "Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors",
abstract = "Little is known about molecular mechanisms for long-lasting neuroadaptation related to the rewarding effects of methamphetamine (MAP). In the present study, we examined the intracellular signaling that is associated with the expression of conditioned place preference (CPP) induced by MAP in rats. Rats were given MAP or saline (control group) for conditioning to the CPP test. MAP-treated and control animals were killed immediately after the CPP test [CPP+]. Some of the MAP-treated rats were killed without the CPP test [CPP-]. Hyperphosphorylation of mitogen-activated protein kinase (MAPK) ERK1/2, but not p38 and c-Jun N-terminal kinase/stress-activated protein kinase, was found in the nucleus accumbens (NAc) and striatum but not in other brain areas of MAP-treated CPP+ animals. No such phosphorylation was seen in control and MAP-treated CPP- animals. Moreover, the transcription factor ets-like gene-1 (Elk-1), but not cAMP response element-binding protein, also showed a similar hyperphosphorylation in the same regions of MAP-treated CPP+. Tyrosine kinase receptors, including tyrosine kinase B, were not activated in any brain regions examined in all groups. Both the dopamine D1 receptor antagonist R-(+)-7-chloro-8-hydroxy-3- methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH23390) and the D2 receptor antagonist raclopride inhibited the expression of CPP as well as the activation of ERK1/2 in MAP-treated CPP+ animals, when they were injected before the CPP test. The microinjection of 2′-amino-3′- methoxyflavone (PD98059), a selective MAPK kinase inhibitor, into the NAc before the test, abolished the MAP-induced ERK1/2 activation and decreased the expression of MAP-induced CPP. These results suggest the importance of the ERK1/2 signaling pathway through activation of dopamine D1 and D2 receptors in the expression of CPP induced by MAP.",
author = "Hiroyuki Mizoguchi and Kiyofumi Yamada and Makoto Mizuno and Tomoko Mizuno and Atsumi Nitta and Yukihiro Noda and Toshitaka Nabeshima",
year = "2004",
month = "5",
day = "1",
doi = "10.1124/mol.65.5.1293",
language = "English",
volume = "65",
pages = "1293--1301",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors. / Mizoguchi, Hiroyuki; Yamada, Kiyofumi; Mizuno, Makoto; Mizuno, Tomoko; Nitta, Atsumi; Noda, Yukihiro; Nabeshima, Toshitaka.

In: Molecular Pharmacology, Vol. 65, No. 5, 01.05.2004, p. 1293-1301.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors

AU - Mizoguchi, Hiroyuki

AU - Yamada, Kiyofumi

AU - Mizuno, Makoto

AU - Mizuno, Tomoko

AU - Nitta, Atsumi

AU - Noda, Yukihiro

AU - Nabeshima, Toshitaka

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Little is known about molecular mechanisms for long-lasting neuroadaptation related to the rewarding effects of methamphetamine (MAP). In the present study, we examined the intracellular signaling that is associated with the expression of conditioned place preference (CPP) induced by MAP in rats. Rats were given MAP or saline (control group) for conditioning to the CPP test. MAP-treated and control animals were killed immediately after the CPP test [CPP+]. Some of the MAP-treated rats were killed without the CPP test [CPP-]. Hyperphosphorylation of mitogen-activated protein kinase (MAPK) ERK1/2, but not p38 and c-Jun N-terminal kinase/stress-activated protein kinase, was found in the nucleus accumbens (NAc) and striatum but not in other brain areas of MAP-treated CPP+ animals. No such phosphorylation was seen in control and MAP-treated CPP- animals. Moreover, the transcription factor ets-like gene-1 (Elk-1), but not cAMP response element-binding protein, also showed a similar hyperphosphorylation in the same regions of MAP-treated CPP+. Tyrosine kinase receptors, including tyrosine kinase B, were not activated in any brain regions examined in all groups. Both the dopamine D1 receptor antagonist R-(+)-7-chloro-8-hydroxy-3- methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH23390) and the D2 receptor antagonist raclopride inhibited the expression of CPP as well as the activation of ERK1/2 in MAP-treated CPP+ animals, when they were injected before the CPP test. The microinjection of 2′-amino-3′- methoxyflavone (PD98059), a selective MAPK kinase inhibitor, into the NAc before the test, abolished the MAP-induced ERK1/2 activation and decreased the expression of MAP-induced CPP. These results suggest the importance of the ERK1/2 signaling pathway through activation of dopamine D1 and D2 receptors in the expression of CPP induced by MAP.

AB - Little is known about molecular mechanisms for long-lasting neuroadaptation related to the rewarding effects of methamphetamine (MAP). In the present study, we examined the intracellular signaling that is associated with the expression of conditioned place preference (CPP) induced by MAP in rats. Rats were given MAP or saline (control group) for conditioning to the CPP test. MAP-treated and control animals were killed immediately after the CPP test [CPP+]. Some of the MAP-treated rats were killed without the CPP test [CPP-]. Hyperphosphorylation of mitogen-activated protein kinase (MAPK) ERK1/2, but not p38 and c-Jun N-terminal kinase/stress-activated protein kinase, was found in the nucleus accumbens (NAc) and striatum but not in other brain areas of MAP-treated CPP+ animals. No such phosphorylation was seen in control and MAP-treated CPP- animals. Moreover, the transcription factor ets-like gene-1 (Elk-1), but not cAMP response element-binding protein, also showed a similar hyperphosphorylation in the same regions of MAP-treated CPP+. Tyrosine kinase receptors, including tyrosine kinase B, were not activated in any brain regions examined in all groups. Both the dopamine D1 receptor antagonist R-(+)-7-chloro-8-hydroxy-3- methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH23390) and the D2 receptor antagonist raclopride inhibited the expression of CPP as well as the activation of ERK1/2 in MAP-treated CPP+ animals, when they were injected before the CPP test. The microinjection of 2′-amino-3′- methoxyflavone (PD98059), a selective MAPK kinase inhibitor, into the NAc before the test, abolished the MAP-induced ERK1/2 activation and decreased the expression of MAP-induced CPP. These results suggest the importance of the ERK1/2 signaling pathway through activation of dopamine D1 and D2 receptors in the expression of CPP induced by MAP.

UR - http://www.scopus.com/inward/record.url?scp=2142655891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142655891&partnerID=8YFLogxK

U2 - 10.1124/mol.65.5.1293

DO - 10.1124/mol.65.5.1293

M3 - Article

C2 - 15102958

AN - SCOPUS:2142655891

VL - 65

SP - 1293

EP - 1301

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 5

ER -